

Clinical Abstracts (Clinical manifestations and disease course in Systemic Sclerosis) Oral Presentations – 4th June, 08:15-09:30 (Victoria Room 5 & 6)

- 08:35 - 08:45: **Validation of the ILD-RISC score in special populations from the EUSTAR registry: tailored cut-off values for non-Caucasian ethnicities, patients with pulmonary hypertension and very early pre-disease** – Maria Iacovantuono (Italy)
- 08:45 - 08:55: **Clinical value of modified EUSTAR disease activity index to stratify for clinical outcome: A longitudinal Observational Analysis of the EUSTAR Database** – Tânia Santiago (Portugal)
- 09:25 - 09:35: **Features of pulmonary Veno-Occlusive Disease complicate the course of precapillary pulmonary hypertension in Systemic Sclerosis: A EUSTAR Cohort Study** – Nicola Farina (Italy)

Poster Tour IV (Taking care of Systemic Sclerosis): Presentations – 5th June, 16:00-17:00

- 17:03 - 17:09: **Immunosuppressants prevent digital ulcers in systemic sclerosis: evidence from a EUSTAR effectiveness study** – Cosimo Bruni (Switzerland)

Poster View I: Presentations – 3rd June, 15:30-16:30

- **Clinical Characterization of Systemic Sclerosis in Egypt: A Multicenter Study from the Egyptian EUSTAR Cohort** – Rahma A. Elziaty (Egypt)
- **Oral anticoagulants do not improve the prognosis of precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study** – Nicola Farina (Italy)
- **Deciphering arthritis in systemic sclerosis: prevalence, clinical phenotype and prognosis in the EUSTAR cohort (CP 151)** – Blaz Burja (Switzerland)
- **Effect of adding oral glucocorticoids to immunosuppression on lung function in systemic sclerosis-associated interstitial lung disease: a target trial emulation study from the European Scleroderma Trial and Research Group database** – Zubeyir Salis (France)
- **Interstitial lung disease in limited cutaneous systemic sclerosis: risk factors and trajectories in the EUSTAR cohort** – Antonio Tonutti (Italy)
- **Does mRSS at 6 months predict mRSS at 12 months follow-up in patients with early diffuse systemic sclerosis? A EUSTAR/RISE-SSc study** – Carina Mihai (Switzerland)
- **Real-world evidence prevalence and clinical outcome of patients meeting the inclusion criteria of the Phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab in SSc) - A EUSTAR cohort study** – Lesley-Anne Bissell (Northern Ireland)
- **Improvement of nailfold microvascular changes over time in patients with systemic sclerosis: a EUSTAR study** – Carina Mihai (Switzerland)
- **DLCO decline is associated with increased vascular risk in systemic sclerosis, primarily driven by pulmonary arterial hypertension: EUSTAR database analysis** – Gonçalo Boleto (Portugal)
- **Prediction of future significant organ involvement in very early and mild systemic sclerosis: a EUSTAR analysis** – Madeleine Venables (Switzerland)
- **Data-driven clinical clusters in ACA-positive systemic sclerosis are associated with disease evolution and organ-specific prognosis: Data from the EUSTAR cohort** – Jelena Colic (Serbia)
- **Incidence, timing, and predictors of new onset gastrointestinal involvement in systemic sclerosis: a longitudinal cohort study from the EUSTAR database** – Francesco Bonomi (Italy)

- **Rethinking skin assessment: analysis of individual Rodnan skin sites scores in early diffuse systemic sclerosis using the EUSTAR cohort** – Tânia Santiago (Portugal)

Poster View VII: Presentations – 5th June, 16:00-17:00

- **Defining the natural history of systemic sclerosis-associated interstitial lung disease to predict the first episode of functional progression: a EUSTAR analysis (EUSTAR CP196)** – Maria Iacovantuono (Italy)
- **Persistent Systemic Inflammation Defines a Distinct High-Risk Phenotype in Systemic Sclerosis: An EUSTAR registry analysis** – Cristiana Sieiro Santos (United Kingdom)
- **Association of Anti-RNA Polymerase III antibodies with Silicone Breast Implants in Systemic Sclerosis patients: update of a multicentre EUSTAR Case-Control Study** – Maria Grazia Lazzaroni (Italy)